生长抑素受体亚型在胰腺癌组织的表达研究

目的:探讨生长抑素受体亚型(SSTR1～5)在胰腺癌组织中的表达及临床病理学意义,为临床生长抑素治疗胰腺肿瘤提供理论依据. 方法:采用免疫组化EnVisionTM 法检测50例胰腺癌组织中生长抑素受体(SSTR)5种亚型的表达. 结果:SSTR1～5亚型在胰腺癌组织中均有表达,但表达强弱有明显差异.SSTR1表达阳性率为50%,SSTR2为94%,SSTR3为82%,SSTR4为90%,SSTR5为96%.胰腺癌SSTR表达优势是SSTR5＞SSTR2＞SSTR4＞SSTR3＞SSTR1(P＜0.01).胰腺癌SSTR各亚型表达阳性率与病人年龄、性别、肿瘤部位和大小、肿瘤组织分化程度及肿瘤分期无统计学意义(P＞0.05). 结论:胰腺癌组织中有SSTR1～5表达,可为将来生长抑素及其类似物治疗胰腺癌提供理论依据.免疫组化方法分析胰腺癌组织中SSTR各亚型表达,可作为病理学分析肿瘤组织中SSTR亚型表达的常规方法.

Expression of somatostatin receptor subtypes in human pancreatic cancer

Objective: To detect the expression of SSTR1,SSTR2,SSTR3,SSTR4 and SSTR5(SSTR1-5)in human pancreatic cancer and discuss their relationships with cliniopathological features.Methods: Immunohistochemical staining of 5 SSTR subtypes was performed by the EnVisionTM technique for paraffin sections of 50 cases of pancreatic cancer.The relationship between the 5 SSTR subtypes expression in pancreatic cancers and the clinicopathological parameters was analyzed.Results: The expression rate of somatostatin receptor subtype-1,subtype-2,subtype-3,subtype-4,subtype-5 in the specimens of pancreatic cancer was 50%,94%,82%,90% and 96%,respectively.The rank order of SSTR subtypes positive expression in pancreatic cancer tissues was SSTR5>SSTR2>SSTR4>SSTR3>SSTR1(P<0.01).No difference of SSTR1-5 expression rate between age,sex,location,tumor size, histological grading and pathological staging was found(P>0.05). Conclusion: SSTR1-5 was detected in human pancreatic cancer,which provided evidence for SST and somatostatin analogs therapy in human pancreatic cancer in the future.The expression rate of SSTR1-5 did not correlate with age,sex,location,tumor size,histological grading and pathological staging of the pancreatic cancer.